A summary of the included study characteristics. by Zahra Tajik (20752452)

Subjects:

NIH score. by Zahra Tajik (20752452)

Subjects:

List of excluded studies. by Zahra Tajik (20752452)

Subjects:

Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration. by Denis Mustafov (19137870)

“…<p><b>(A)</b> A significant decrease in the proliferative clonal capacity of U87MG colonies was observed with 70ΜM and 100ΜM SHG-44 treatment. …”

Join-point regression analysis of the statistically significant linear increase in use of antidepressants during the observed time period. by Jelena Filimonovic (22305307)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

Alterations in CBC parameters in albino rats of both genders after 60 days of administration of dimethoate presented in Mean ± S.E.M. and their significance level. by Nida Saleem (17194610)

Subjects:

Alterations in CBC parameters in albino rats of both genders after 30 days of administration of dimethoate presented in Mean ± S.E.M. and their significance level. by Nida Saleem (17194610)

Subjects:

Alterations in CBC parameters in albino rats of both genders after 90 days of administration of dimethoate presented in Mean ± S.E.M. and their significance level. by Nida Saleem (17194610)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

S1 Data - by Kazuyoshi Ohkawa (836847)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects: